High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.

Abstract

Infants and young children, especially those in day care, are at risk for recurrent or persistent acute otitis media (AOM). There are no data on oral alternatives to high-dose amoxicillin-clavulanate for treating AOM in these high-risk patients. In this double-blind, double-dummy multicenter clinical trial, we compared a novel, high-dose azithromycin regimen with high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent AOM. Three hundred four children were randomized; 300 received either high-dose azithromycin (20 mg/kg of body weight once a day for 3 days) or high-dose amoxicillin-clavulanate (90 mg/kg divided twice a day for 10 days). Tympanocentesis was performed at baseline; clinical response was assessed at day 12 to 16 and day 28 to 32. Two-thirds of patients were aged < or =2 years. A history of recurrent, persistent, or recurrent plus persistent AOM was noted in 67, 18, and 14% of patients, respectively. Pathogens were isolated from 163 of 296 intent-to-treat patients (55%). At day 12 to 16, clinical success rates for azithromycin and amoxicillin-clavulanate were comparable for all patients (86 versus 84%, respectively) and for children aged < or =2 years (85 versus 79%, respectively). At day 28 to 32, clinical success rates for azithromycin were superior to those for amoxicillin-clavulanate for all patients (72 versus 61%, respectively; P = 0.047) and for those aged < or =2 years (68 versus 51%, respectively; P = 0.017). Per-pathogen clinical efficacy against Streptococcus pneumoniae and Haemophilus influenzae was comparable between the two regimens. The rates of treatment-related adverse events for azithromycin and amoxicillin-clavulanate were 32 and 42%, respectively (P = 0.095). Corresponding compliance rates were 99 and 93%, respectively (P = 0.018). These data demonstrate the efficacy and safety of high-dose azithromycin for treating recurrent or persistent AOM.

• Authors: Antonio Arrieta, Adriano Arguedas, Pilar Fernandez, Stan L Block, Paz Emperanza, Sergio L Vargas, William A Erhardt, Pascal J de Caprariis, Constance D Rothermel
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 47 Issue 10 Pg. 3179-86 (Oct 2003) ISSN: 0066-4804 [Print] United States
• PMID: 14506028 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Penicillins
• Amoxicillin-Potassium Clavulanate Combination
• Azithromycin

Topics

• Acute Disease
• Amoxicillin-Potassium Clavulanate Combination (adverse effects, therapeutic use)
• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Azithromycin (adverse effects, therapeutic use)
• Child
• Child, Preschool
• Double-Blind Method
• Drug Therapy, Combination (adverse effects, therapeutic use)
• Female
• Humans
• Infant
• Male
• Microbial Sensitivity Tests
• Otitis Media (drug therapy, microbiology)
• Patient Compliance
• Penicillins (pharmacology)
• Recurrence
• Treatment Outcome